Compare Incyte Corporation (INCY) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Short Term Corporate Bond ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 2.3× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| INCY | VCSH | |
|---|---|---|
Market Cap | $22.85B | $51.90B |
Volume | 1,927,029 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $129.93 | $80.20 |
52-Week Low | $83.80 | $77.03 |
Typical Hold Time | 33 Days | 52 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.34 with a slight 0.09% daily gain. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its competitive 4.5% dividend yield and low 0.03% expense ratio, though some analysts note tight credit spreads and downgrade it to 'Hold'. The fund's short 2.7-year duration minimizes interest rate risk but carries corporate credit exposure.
The ETF offers a higher yield than treasury alternatives but faces headwinds from limited price appreciation potential amid rising rates and compressed spreads. Key risks include credit deterioration and institutional selling. Analyst sentiment is mixed, balancing yield appeal against near-term unattractive entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
